Stably Expressing
EGFR Mutant Cell Lines
Signosis offers a comprehensive panel of stably expressing EGFR mutant cell lines representing key mutation classes for studying cancer biology, drug resistance mechanisms, and screening targeted therapies.
Principle
EGFR mutations occur in many cancers, including non-small cell lung cancer (NSCLC). The most common are deletions in exon 19 (Del19) and L858R in exon 21, which confer sensitivity to first- and second-generation TKIs (gefitinib, erlotinib, afatinib). Resistance almost always develops, with T790M in exon 20 found in over half of post-TKI progression cases. Double mutations like L858R + T790M and Del19 + T790M result in strong resistance to apoptosis upon TKI treatment, posing a clinical challenge.
To combat this challenge, Signosis has created a collection of Stably Expressing EGFR Mutant Cell Lines. These cell lines are ideal for studying the molecular mechanisms of drug susceptibility, development of resistance, and for screening or validating new TKIs.
Comprehensive EGFR Mutant Cell Line Collection
Signosis offers a wide variety of EGFR mutant cell lines that reflect key mutation classes with distinct biological functions and drug sensitivity profiles to supports advanced cancer research and drug development, including:
Classical-like Mutations
Mutations typically sensitive to first- and second-generation EGFR TKIs:
-
L858R
-
Del19
-
Del19 + T790M
-
A767_dupASV
Note: Del19 + T790M is both a classical driver and resistance mutation.
Exon 20 Loop Insertion Mutations
Insertions in the loop at the C-terminal end of the αC-helix in exon 20, often causing drug resistance:
-
H773_V774insNPH
-
D770_N771insSVD
-
H773_V774insH
-
A763_Y764insFQEA
-
M766_A767insAI
-
Y764_V765insHH
T790M-like Mutations
Mutations that generally confer resistance to first- and second-generation EGFR TKIs:
-
T790M
-
L792H
-
C797S
-
Del19 + T790M
-
Mutations with T790M and/or C797S
P-loop and αC-helix Compression (PACC) Mutations
Mutations affecting the ATP-binding pocket that cause compression, impacting drug binding affinity.
-
L718Q
-
L792H
Explore how our engineered cell lines can accelerate your research in developing next-generation therapies or understanding resistance. Contact us for technical datasheets or to discuss custom cell line requests.
